Who is Included?
You are a member of the Class(es) if you are a third-party payor and you purchased or provided reimbursement for prescription drugs as
(1) Generic Nexium Nationwide Class. Between May 27, 2014 and February 1, 2019, you purchased or paid for some or all of the purchase price of AB-rated generic versions of Nexium in the United States and its territories;
(2) Brand or Generic Diovan Nationwide Class. Between September 28, 2012 and April 1, 2020, you purchased or paid for some or all of the purchase price of Diovan and/or AB-rated generic versions of Diovan in the United States and its territories; or
(3) Brand or Generic Valcyte Nationwide Class. Between August 1, 2014 and April 1, 2020, you purchased or paid for some or all of the purchase price of Valcyte and/or AB-rated generic versions of Valcyte in the United States and its territories.
Excluded from all of the Classes are: natural person consumers; Defendants, their officers, directors, management, employees, subsidiaries, and affiliates; all federal and state governmental entities except for cities, towns, municipalities, or counties with self-funded prescription drug plans; all persons or entities who purchased the at-issue drugs for purposes of resale from any of the Defendants or any brand or generic manufacturer; fully insured health plans (i.e., health plans that purchased insurance covering 100% of their reimbursement obligation to members); and pharmacy benefit managers.
For additional details, please read the Long Form Notice.
|YOUR LEGAL RIGHTS AND OPTIONS|
|DO NOTHING||If you are a member of a Class, by doing nothing you will remain in that Class but will not be entitled to share in any distribution from the Settlement Fund. You will be bound by any decision of the Court in this Lawsuit, including rulings on the Settlement. See Question 11 of the Notice.|
|SUBMIT A CLAIM FORM||If you did not exclude yourself from one or more of the classes prior to the December 20, 2021 deadline and believe you are a Class Member, you will need to complete and return a claim form to obtain a share of the Settlement Fund. The claim form, and information on how to submit it, are available on the Claim Form page of this website. Proofs of Claim must be postmarked (if mailed) or received (if submitted online) on or before October 11, 2022. See Question 7 of the Notice.|
|OBJECT TO THE SETTLEMENT OR SPEAK AT THE FAIRNESS HEARING||If you object to all or any part of the Settlement or desire to speak in person at the Fairness Hearing, you must file a written letter of objection and/or a notice of intention to speak along with a summary statement with the Court and with Lead Class Counsel and Counsel for Ranbaxy by July 18, 2022. See Question 10 of the Notice.|
|GET MORE INFORMATION||
If you would like more information about the Lawsuit, you can review the Notice and send questions to the Settlement
Administrator and/or Lead Class Counsel. See Questions 12 and 18 of the Notice.
DO NOT CONTACT THE COURT OR THE DEFENDANTS IF YOU HAVE QUESTIONS REGARDING THE NOTICE.